Trial reportThe Indian journal of medical research2026
Saroglitazar for non-obese metabolic-dysfunction associated steatotic liver disease (MASLD): An open-label randomised controlled trial.
Trial report in The Indian journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives Nearly one-third of individuals with metabolic dysfunction-associated steatotic liver disease (MASLD)/non-alcoholic fatty liver disease (NAFLD) are non-obese, yet evidence for pharmacotherapy in this subgroup remains limited. This study assessed the safety and effectiveness of saroglitazar among non-obese individuals with MASLD/NAFLD. Methods In this open-label randomised controlled trial (RCT), non-obese [body mass index (BMI) <25 kg/m2] adults with NAFLD/MASLD and raised alanine aminotransferase levels (ALT >50 U/L) were allocated in a 1:1 ratio to either saroglitazar (4 mg/day) combined with lifestyle modification (Group A) or lifestyle intervention alone (Group B) for a period of six months. The trial was registered with clinical trial registry (CTRI/2022/09/046081). The primary outcome was the change in controlled attenuation parameter (CAP). Secondary outcomes included changes in anthropometric measures, insulin resistance, glycaemic indices, lipid profile, ALT, fibroscan-aspartate aminotransferase (FAST) score, hepatic steatosis index (HSI), non-invasive fibrosis markers [liver stiffness measurement (LSM), fibrosis-4 (FIB-4), aspartate aminotransferase to platelet ratio index (APRI),], and adverse events. Results Sixty-six participants (33 per group) completed the study. Both groups showed significant reductions in CAP; however, the median change in CAP did not differ between the two groups [24 dB/m (9-48.8) vs. 14 dB/m (-4.5 to 50); P=0.52]. Alterations in BMI and waist circumference were similar between groups. Homeostasis model assessment-estimated insulin resistance (HOMA-IR) [0.68 (0.14-1.69) vs. -0.51 (-1.12 to 0.44); P=0.03], triglycerides [34 (-1.5 to 76.8) vs. -10 (-28.5 to 20.5) mg/dL; P=0.006], and ALT (43.7±36.7 vs. 28.1±21.5 U/L; P=0.04) were significantly improved in the saroglitazar group. Changes in HSI, FAST score, APRI, FIB-4, and liver stiffness were similar between groups. No serious adverse events were observed. Interpretation and conclusions In non-obese NAFLD/MASLD patients, the combination of saroglitazar with lifestyle changes over a period of six months improved insulin resistance, triglycerides, and ALT but did not confer additional benefit over lifestyle intervention alone for non-invasive hepatic steatosis or liver fibrosis markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.